Mujie Lin

MiniMax, Aili Chen, Aonian Li et al.

We introduce MiniMax-M1, the world's first open-weight, large-scale hybrid-attention reasoning model. MiniMax-M1 is powered by a hybrid Mixture-of-Experts (MoE) architecture combined with a lightning attention mechanism. The model is developed based on our previous MiniMax-Text-01 model, which contains a total of 456 billion parameters with 45.9 billion parameters activated per token. The M1 model natively supports a context length of 1 million tokens, 8x the context size of DeepSeek R1. Furthermore, the lightning attention mechanism in MiniMax-M1 enables efficient scaling of test-time compute. These properties make M1 particularly suitable for complex tasks that require processing long inputs and thinking extensively. MiniMax-M1 is trained using large-scale reinforcement learning (RL) on diverse problems including sandbox-based, real-world software engineering environments. In addition to M1's inherent efficiency advantage for RL training, we propose CISPO, a novel RL algorithm to further enhance RL efficiency. CISPO clips importance sampling weights rather than token updates, outperforming other competitive RL variants. Combining hybrid-attention and CISPO enables MiniMax-M1's full RL training on 512 H800 GPUs to complete in only three weeks, with a rental cost of just $534,700. We release two versions of MiniMax-M1 models with 40K and 80K thinking budgets respectively, where the 40K model represents an intermediate phase of the 80K training. Experiments on standard benchmarks show that our models are comparable or superior to strong open-weight models such as the original DeepSeek-R1 and Qwen3-235B, with particular strengths in complex software engineering, tool utilization, and long-context tasks. We publicly release MiniMax-M1 at https://github.com/MiniMax-AI/MiniMax-M1.

Liye Chen, Biaoshun Li, Yihao Chen et al.

Antibody-drug conjugate (ADC) has revolutionized the field of cancer treatment in the era of precision medicine due to their ability to precisely target cancer cells and release highly effective drug. Nevertheless, the realization of rational design of ADC is very difficult because the relationship between their structures and activities is difficult to understand. In the present study, we introduce a unified deep learning framework called ADCNet to help design potential ADCs. The ADCNet highly integrates the protein representation learning language model ESM-2 and small-molecule representation learning language model FG-BERT models to achieve activity prediction through learning meaningful features from antigen and antibody protein sequences of ADC, SMILES strings of linker and payload, and drug-antibody ratio (DAR) value. Based on a carefully designed and manually tailored ADC data set, extensive evaluation results reveal that ADCNet performs best on the test set compared to baseline machine learning models across all evaluation metrics. For example, it achieves an average prediction accuracy of 87.12%, a balanced accuracy of 0.8689, and an area under receiver operating characteristic curve of 0.9293 on the test set. In addition, cross-validation, ablation experiments, and external independent testing results further prove the stability, advancement, and robustness of the ADCNet architecture. For the convenience of the community, we develop the first online platform (https://ADCNet.idruglab.cn) for the prediction of ADCs activity based on the optimal ADCNet model, and the source code is publicly available at https://github.com/idrugLab/ADCNet.